However, we confirmed the same trend in TCGA cohort, and there are other reports in a large cohort study with over 40 000 cases that ARID1A‐mutated cancers including CRCs had higher mutational burdens than cancers without ARID1A mutations.12, 14. This evidence concerns the gene ARID1A and cancer.